Cantor Fitzgerald Maintains Structure Therapeutics(GPCR.US) With Buy Rating, Maintains Target Price $65
Structure Therapeutics Analyst Ratings
Cantor Fitzgerald Sticks to Their Buy Rating for Structure Therapeutics, Inc. Sponsored ADR (GPCR)
Morgan Stanley Initiates Structure Therapeutics(GPCR.US) With Buy Rating, Announces Target Price $118
Buy Rating for Structure Therapeutics: GSBR-1290's Market Potential in Diabesity
Structure Therapeutics Analyst Ratings
JMP Securities Maintains Structure Therapeutics(GPCR.US) With Buy Rating, Maintains Target Price $86
Buy Rating on Structure Therapeutics: Promising GSBR-1290 Clinical Developments and Competitive Market Positioning
Jefferies Maintains Structure Therapeutics(GPCR.US) With Buy Rating, Maintains Target Price $79
Piper Sandler Maintains Structure Therapeutics(GPCR.US) With Buy Rating, Maintains Target Price $93
Structure Therapeutics, Inc. Sponsored ADR (GPCR) Receives a Buy From Piper Sandler
Structure Therapeutics Analyst Ratings
Cantor Fitzgerald Maintains Structure Therapeutics(GPCR.US) With Buy Rating, Maintains Target Price $65
Structure Therapeutics Analyst Ratings
Cantor Fitzgerald Reiterates Overweight on Structure Therapeutics, Maintains $65 Price Target
Analysts Offer Insights on Healthcare Companies: Structure Therapeutics, Inc. Sponsored ADR (GPCR) and AbSci (ABSI)
Buy Rating Affirmed for Structure Therapeutics on Strong Pipeline and Undervalued Patent Portfolio
Don't Forget This Startup's Weight-Loss Pill, Analyst Says -- Barrons.com
Structure Therapeutics Analyst Ratings
Leerink Partners Maintains Structure Therapeutics(GPCR.US) With Buy Rating, Announces Target Price $136